Skip to main content
. Author manuscript; available in PMC: 2025 Sep 24.
Published in final edited form as: Mol Cancer Ther. 2021 Feb 25;20(5):846–858. doi: 10.1158/1535-7163.MCT-20-0476

Table 3:

Characteristics of the r/r B-ALL patients recruited in the study

Case No. Patient ID Age (Yrs) Lymphoma / Leukemia type Number of prior lines of therapy
CH26365 5 8 Relapsed First line chemotherapy followed by High-risk relapse
CP23182 8 12 Relapsed First line chemotherapy followed by High-risk relapse and salvage chemotherapy
CP42698 10 9 Refractory First-line chemotherapy- refractory, and given 2nd-line chemotherapy
CR11792 13 21 Refractory First-line chemotherapy- refractory, and given 2nd-line chemotherapy
CN16436 18 7 Relapsed First line chemotherapy followed by High-risk relapse and salvage chemotherapy